BridgeBio Pharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
BridgeBio Pharma, Inc. (BBIO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$437.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-24
- BridgeBio Pharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$437.61M.
- BridgeBio Pharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$207.79M.
- BridgeBio Pharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$565.84M.
- BridgeBio Pharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$485.08M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$437.61M 10-K · filed 2026-02-24 | |
| 2024-12-31 | -$207.79M 10-K · filed 2026-02-24 | |
| 2023-12-31 | -$565.84M 10-K · filed 2026-02-24 | |
| 2022-12-31 | -$485.08M 10-K · filed 2025-02-20 | |
| 2021-12-31 | -$586.48M 10-K · filed 2024-02-22 | |
| 2020-12-31 | -$505.49M 10-K · filed 2023-02-23 | $505.49M 10-K · filed 2021-02-25 |
| 2019-12-31 | -$288.58M 10-K · filed 2022-02-25 | $288.58M 10-K · filed 2020-03-03 |
| 2018-12-31 | $169.45M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $43.83M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |